Mantle Cell Lymphoma
Conference Coverage
Lenalidomide maintenance improves MCL survival after ASCT
SAN DIEGO – PFS was better post transplant with lenalidomide maintenance, but it’s too early to know whether OS will be improved.
From the Journals
Cortactin expression aids in CLL-MCL differential
Cortactin, a cytoskeleton-remodeling adapter protein, is expressed on most CLL cells, but not similar-appearing MCL cells.
Conference Coverage
Relapsed MCL: Options for treatment
There are a number of treatment options for relapsed MCL, but BTK inhibitors are particularly useful.
From the Journals
First-line bortezomib prolongs survival in MCL
The survival benefits are promising with the addition of bortezomib, but there was no significant difference among high-risk patients.
From the Journals
Ibrutinib discontinuation harms survival in CLL
A single-institution study examines the impact of early dose reduction of ibrutinib in non-Hodgkin lymphoma and CLL.
Conference Coverage
MCL treatment choices depend partly on age
CHICAGO – There are important treatment differences in patients aged 65 and younger versus those over 65.
Conference Coverage
Prognostic factors guide mantle cell treatment decisions
CHICAGO –
From the Journals
Outpatient lenalidomide/rituximab yields long-term MCL remission
Nearly two-thirds of evaluable patients with mantle cell lymphoma had durable responses to induction and maintenance.
Latest News
New mantle cell trials launching
At least four new mantle cell lymphoma trials were registered in Clinicaltrials.gov in August 2018.
From the Journals
TP53 mutation plus complex karyotype equals poor prognosis
The two markers signaled worse overall survival among mantle cell lymphoma patients.
From the Journals
Adverse events outweigh promise of SGN-CD70A against NHL
Despite a handful of durable remissions of non-Hodgkin lymphomas with the antibody-drug conjugate, thrombocytopenias canceled out the benefit.